Purpose To develop a radiomics signature to estimate disease-free survival (DFS) in patients with early-stage (stage I–II) non–small cell lung cancer (NSCLC) and assess its incremental value to the traditional staging system and clinical-pathologic risk factors for individual DFS estimation. Materia...